Evidence map›Paper›PMID 41364270›Full record

ArticleDiscover oncology2025

Changes in peripheral blood B cell levels predict overall survival in patients with advanced liver cancer treated with immune target inhibitors.

Shifeng Cheng, Jing Tang, Yafeng Mo, Na Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shifeng ChengHangzhou Linping Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
Jing TangDepartment of Orthopedic, Zhejiang Rehabilitation Medical Center, Hangzhou, Zhejiang, China.
Yafeng MoDepartment of Orthopedic, Zhejiang Rehabilitation Medical Center, Hangzhou, Zhejiang, China.
Na WuHangzhou Linping Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, China. nana_wu2025@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PD-1 inhibitors show efficacy in hepatocellular carcinoma (HCC), yet overall outcomes remain poor. In this retrospective study of 258 advanced HCC patients treated between 2019 and 2024, peripheral blood B-cell dynamics were evaluated. Patients with higher B-cell proportions or absolute counts had significantly longer overall survival (OS) and progression-free survival (PFS). Multivariate analysis confirmed elevated B-cell proportion as an independent protective factor for OS. These results suggest that peripheral blood B-cell levels may serve as prognostic biomarkers for PD-1-based immunotherapy in advanced HCC.

Indexed as

B cellsHepatocellular carcinomaImmune checkpoint inhibitorsImmunotherapyPrognostic markers

Identifiers

PMID41364270
PMCPMC12799869

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.